Physician profile
Brittani Orme
NPI 1154076453
$2,869.95
in general payments reported to CMS, 2019-2025
29 companies · $573 in 2025
The $573 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $437 · 2023: $1,306 · 2024: $554 · 2025: $573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,146 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,145.53 |
| Education | $287.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $780.69 | 2023-2025 | Veozah, Myrbetriq |
| Myriad Women'S Health, INC. | $222.49 | 2023 | Myrisk |
| Organon LLC | $215.20 | 2022-2025 | Nexplanon |
| Pfizer INC. | $200.63 | 2023-2025 | |
| Sage Therapeutics, LLC | $163.34 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $135.32 | 2022-2025 | Slynd |
| Mayne Pharma Commercial LLC | $131.00 | 2022-2025 | |
| Agile Therapeutics, INC. | $129.21 | 2022-2024 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $101.51 | 2022-2024 | |
| Daiichi Sankyo INC. | $92.90 | 2022-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $76.74 | 2023 | Myfembree |
| Millicent US INC | $73.91 | 2022-2024 | Intrarosa, Femring |
| Biohaven Pharmaceutical Holding Company Ltd. | $60.53 | 2022 | |
| Exact Sciences Corporation | $56.38 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $56.14 | 2023-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $43.13 | 2024 | Impella |
| Myovant Sciences INC. | $41.47 | 2022 | |
| Hologic Sales and Service, LLC | $38.16 | 2024-2025 | Aptima, Thinprep 2000 Processor, Novasure |
| Scynexis, INC. | $36.59 | 2022 | |
| Supernus Pharmaceuticals, INC. | $32.77 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $29.56 | 2025 | Solosec, Phexx, Phexxi |
| Coopersurgical, INC. | $23.55 | 2024 | Paragard T 380a |
| Becton, Dickinson and Company | $20.68 | 2023 | Bd Affirm Vpiii Microbial Identification Test |
| Idorsia Pharmaceuticals US INC | $19.50 | 2023 | Quviviq |
| Duchesnay USA Incorporated | $18.81 | 2022 | |
| Integra Lifesciences Corporation | $18.52 | 2023 | Biodoptix, Biodfactor, Biofix |
| Mylan Pharmaceuticals INC. | $17.49 | 2022 | |
| Axonics, INC. | $17.01 | 2023 | Axonics |
| Avanos Medical | $16.72 | 2023 | On-Q* Pump and Accessories |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittani Orme listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.